natgillin/translations-raw huggingface dataset:
In clinical trials in a range of indications including allergic rhinitis and chronic idiopathic urticaria, at the recommended dose of 5 mg daily, undesirable effects with Neoclarityn were reported in 3 % of patients in excess of those treated with placebo.
V kliničnih preskušanjih pri različnih indikacijah za uporabo zdravila, vključno z alergijskim rinitisom in kronično idiopatsko urtikarijo so pri priporočenem odmerku 5 mg na dan o neželenih učinkih zdravila Neoclarityn poročali pri 3 % bolnikov več kot pri tistih, ki so bili zdravljeni s placebom.
In clinical trials in cancer patients the most frequent undesirable effect was musculoskeletal pain which was mild or moderate in 10%, and severe in 3% of patients.
V kliničnih preizkušanjih pri bolnikih z rakom je bil najpogostejši neželen učinek mišično-skeletna bolečina, ki je bila pri 10% bolnikov blaga ali zmerna, in pri 3% bolnikov huda.
In clinical trials in cancer patients the most frequent undesirable effect was musculoskeletal pain which was mild or moderate in 10%, and severe in 3% of patients.
V kliničnih preskušanjih pri bolnikih z rakom je bil najpogostejši neželeni učinek mišično-skeletna bolečina, ki je bila blaga do zmerna pri 10 % bolnikov,in huda pri 3 % bolnikov.
In clinical trials in cats this product reduced pain and inflammation associated with musculoskeletal disorders and reduced the need for rescue treatment when given as premedication in case of orthopaedic surgery, in combination with opioids.
To zdravilo je v kliničnih poskusih na mačkah zmanjšalo bolečino in vnetje v povezavi z mišičnoskeletnimi obolenji ter potrebo po uporabi drugih hitro delujočih zdravil za lajšanje bolečin, kadar so ga dajali kot premedikacijo v kombinaciji z opioidi v primeru ortopedskih operativnih posegov.
In clinical trials in cats, robenacoxib tablets reduced pain and inflammation associated with musculoskeletal disorders and reduced the need for rescue treatment when given as premedication in case of orthopaedic surgery, in combination with opioids.
V kliničnih poskusih na mačkah so tablete robenakoksiba zmanjšale bolečino in vnetje v povezavi z mišičnoskeletnimi obolenji ter potrebo po uporabi drugih hitro delujočih zdravil za lajšanje bolečin, kadar so jih dajali kot premedikacijo v kombinaciji z opioidi v primeru ortopedskih operativnih posegov.
In clinical trials in cIAI, the most common type of infection in tigecycline-treated patients was complicated appendicitis (50.3 %), followed by other diagnoses less commonly reported such as complicated cholecystitis (9.6 %), perforation of intestine (9.6 %), intra-abdominal abscess (8.7 %), gastric or duodenal ulcer perforation (8.3 %), peritonitis (6.2 %) and complicated diverticulitis (6.0
V kliničnih preskušanjih pri cIAI je bila najpogostejša vrsta okužb pri bolnikih, zdravljenih s tigeciklinom, vnetje slepiča z zapleti (50,3 %), sledile so mu druge diagnoze, o katerih so redkeje poročali, na primer vnetje žolčnika z zapleti (9,6 %), perforacija črevesa (9,6 %), intraabdominalni absces (8,7 %), perforacija želodčne ali duodenalne razjede (8,3 %), peritonitis (6,2 %) in zapleti divertikulitisa (6,0 %).
In clinical trials in CML, medicinal product discontinuation for medicinal product-related adverse reactions was observed in 2.4% of newly diagnosed patients, 4% of patients in late chronic phase after failure of interferon therapy, 4% of patients in accelerated phase after failure of interferon therapy and 5% of blast crisis patients after failure of interferon therapy.
V kliničnih preskušanjih pri KML so prekinitev dajanja zdravila zaradi neželenih reakcij, povezanih z zdravilom, zabeležili pri 2,4 % na novo diagnosticiranih bolnikov, 4 % bolnikov v pozni kronični fazi po neuspelem zdravljenju z interferonom, 4 % bolnikov v pospešeni fazi po neuspelem zdravljenju z interferonom in 5 % bolnikov v blastni krizi po neuspelem zdravljenju z interferonom.
In clinical trials in elderly patients with dementia, olanzapine treatment was associated with a higher incidence of death and cerebrovascular adverse reactions compared to placebo (see also section 4.4).
V kliničnih preskušanjih pri starejših bolnikih z demenco je bilo zdravljenje z olanzapinom povezano z višjo incidenco smrti in cerebrovaskularnih neželenih reakcij v primerjavi s placebom (glejte poglavje 4.4).
In clinical trials in elderly patients with dementia, olanzapine treatment was associated with a higher incidence of death and cerebrovascular adverse reactions compared to placebo (see section 4.4).
V kliničnih preizkušanjih na starejših bolnikih z demenco je bilo zdravljenje z olanzapinom v primerjavi s placebom povezano z večjo smrtnostjo in pogostejšimi možganskožilnimi neželenimi dogodki (gl. poglavje 4.4).
In clinical trials in epilepsy patients the incidence rate of reported first degree AV Block is uncommon, 0.7%, 0%, 0.5% and 0% for lacosamide 200 mg, 400 mg, 600 mg or placebo, respectively.
V kliničnih preskušanjih pri bolnikih z epilepsijo je bila incidenca atrioventrikularnega bloka prve stopnje opredeljena kot občasni neželeni učinek, ki se je pojavil pri 0,7 %, 0 %, 0,5 % oziroma 0 % bolnikov, ki so jemali lakozamid v odmerku 200 mg, 400 mg, 600 mg oziroma placebo.
In clinical trials in Friedreich’s Ataxia, 32 patients between the ages of 8 and 11 years and 91 patients between the ages of 12 and 17 years received idebenone at ≥ 900 mg/day for up to 42 months.
V kliničnih preskušanjih Friedrichove ataksije je 32 bolnikov, starih od 8 do 11 let, in 91 bolnikov, starih od 12 do 17 let, prejemalo idebenon v odmerku ≥ 900 mg/dan do 42 mesecev.
In clinical trials in mild to severe dementia, involving 1,784 patients treated with memantine and 1,595 patients treated with placebo,the overall incidence rate of adverse reactions with memantine did not differ from those with placebo; the adverse reactions were usually mild to moderate in severity.
V kliničnih preskušanjih bolnikov z zmerno do hudo demenco, ki so zajeli 1784 bolnikov, zdravljenih z memantinom in 1595 bolnikov, ki so prejemali placebo, se skupna incidenca neželenih učinkov pri memantinu ni razlikovala od placeba, neželeni učinki pa so bili po resnosti večinoma blagi do zmerni.
In clinical trials in mild to severe dementia, involving 1,784 patients treated with memantine and 1,595patients treated with placebo, the overall incidence rate of adverse reactions with memantine did not differ from those with placebo; the adverse reactions were usually mild to moderate in severity.
V kliničnih preskušanjih bolnikov z zmerno do hudo demenco, ki so zajeli 1784 bolnikov, zdravljenih z memantinom in 1595 bolnikov, ki so prejemali placebo, se skupna incidenca neželenih učinkov pri memantinu ni razlikovala od placeba, neželeni učinki pa so bili po resnosti večinoma blagi do zmerni.
In clinical trials in patients with drug-induced (dopamine agonist) psychosis associated with Parkinson’s disease, worsening of Parkinsonian symptomatology and hallucinations were reported very commonly and more frequently than with placebo.
V kliničnih preizkušanjih na bolnikih s psihozami, ki so jih povzročila zdravila (dopaminski agonisti), povezana s Parkinsonovo boleznijo, so pogosto ter pogosteje kot pri placebu poročali o poslabšanju simptomatike Parkinsonove bolezni in halucinacijah.
In clinical trials in patients with drug-induced (dopamine agonist) psychosis associated with Parkinson’s disease, worsening of Parkinsonian symptomatology and hallucinations were reported very commonly and more frequently than with placebo.
V kliničnih preskušanjih pri bolnikih s psihozami povzročenimi z zdravili (dopaminski agonisti) povezanimi s Parkinsonovo boleznijo, so pogosto ter pogosteje kot pri placebu poročali o poslabšanju Parkinsonove simptomatologije in halucinacijah.
In clinical trials in patients with drug-induced (dopamine agonist) psychosis associated with Parkinson’s disease, worsening of Parkinsonian symptomatology and hallucinations were reported very commonly and more frequently than with placebo.
V kliničnih preskušanjih pri bolnikih s psihozami povzročenimi z zdravili (dopaminski agonisti) povezanimi s Parkinsonovo boleznijo, so pogosto ter pogosteje kot pri placebu poročali o poslabšanju simptomatologije Parkinsonove bolezni in halucinacijah.
In clinical trials in RA, up to 3% of adult patients tested seropositive at least once during the study for antibodies capable of neutralising the biologic effects of anakinra.
V kliničnih preskušanjih RA je bilo do 3 % odraslih bolnikov vsaj enkrat med študijo seropozitivnih za protitelesa, ki lahko nevtralizirajo biološke učinke anakinre.
In clinical trials in type 1 diabetes, patients using a regimen of EXUBERA in combination with long- or intermediate-acting insulin had similar reductions in HbA1c compared with patients taking subcutaneous insulin alone.
Pri kliničnih preskušanjih pri diabetesu tipa 1 je bilo znižanje HbA1c podobno pri bolnikih, ki so se zdravili s shemo z zdravilom EXUBERA v kombinaciji z dolgo- ali srednjedolgo- delujočim insulinom, in pri bolnikih, ki so se zdravili samo s subkutanim insulinom.
In clinical trials involving over 350 patients, no induction of human anti-mouse antibody (HAMA) to antibody fragments has been observed nor has there been any elevation of HAMA levels in patients with pre-existing HAMA.
V kliničnih študijah, ki so vključevale preko 350 bolnikov, niso opazili indukcije nastanka človeških protiteles proti mišjemu antigenu (HAMA) zaradi vnosa fragmentov mišjih protiteles, ravno tako pa pri bolnikih, ki so HAMA že razvili, niso opazili porasta HAMA vrednosti.
In clinical trials involving patients with relapsed small cell lung cancer, the dose limiting toxicity of oral topotecan monotherapy was found to be haematological.
V kliničnih preskušanjih pri bolnikih z relapsom drobnoceličnega pljučnega raka je bila hematotoksičnost monoterapije s peroralnim topotekanom tista, ki je omejevala njegov odmerek.
In clinical trials involving patients with relapsed small cell lung cancer, the dose limiting toxicity of oral topotecan monotherapy was found to be haematological.
V kliničnih preskušanjih pri bolnikih z relapsom drobnoceličnega pljučnega raka je bila hematotoksičnost monoterapije s peroralnim topotekanom tista, ki je omejevala odmerek.
In clinical trials involving SIMBRINZA dosed twice-daily the most common adverse reactions were ocular hyperaemia and ocular allergic type reactions occurring in approximately 6-7% of patients, and dysgeusia (bitter or unusual taste in the mouth following instillation) occurring in approximately 3% of patients.
V kliničnih preskušanjih z uporabo zdravila SIMBRINZA dvakrat na dan so bili najpogostejši neželeni učinki očesna hiperemija in očesne alergijske reakcije, ki so se pojavili pri približno 6-7% bolnikov, disgevzija (grenak ali nenavaden okus v ustih po vkapanju zdravila) pa se je pojavila pri približno 3% bolnikov.
In clinical trials mean total and LDL cholesterol declined by 15-31%.
Pri kliničnih preskušanjih je povprečna vrednost skupnega holesterola in holesterola LDL upadla za 15 - 31 %.
In clinical trials more than 3100 patients received at least one treatment course and were followed for periods ranging from 6 months to over 5 years; approximately 2400 patients received two or more courses of treatment with over 1000 having received 5 or more courses.
V kliničnih preskušanjih je več kot 3.100 bolnikov prejelo najmanj en cikel zdravljenja, po tem so jih spremljali od 6 mesecev do več kot 5 let; približno 2.400 bolnikov je prejelo dva ali več ciklov zdravljenja, od teh pa več kot 1.000 bolnikov 5 ali več ciklov zdravljenja.
In clinical trials non-cutaneous malignancies were reported in 1% (6/586) of patients with dabrafenib monotherapy, and 1% (3/209) of patients in study MEK115306 and <1% (3/350) of patients in study MEK116513 with dabrafenib in combination with trametinib.
V kliničnih študijah so o nekožnih malignomih poročali pri 1 % (6/586) bolnikov, ki so prejemali dabrafenib v monoterapiji, in pri 1 % (3/209) bolnikov v študiji MEK115306 ter pri < 1 % (3/350) bolnikov v študiji MEK116513 med tistimi, ki so prejemali dabrafenib v kombinaciji s trametinibom.
In clinical trials of 118 children and adolescents (3 to 16 years of age), 6 % discontinued therapy due to adverse reactions.
V kliničnih preskušanjih pri 118 otrocih in mladostnikih (starih od 3 do 16 let) je bilo pri 6 % zdravljenje ukinjeno zaradi neželenih učinkov.
In clinical trials of 118 children and adolescents 3 to 16 years of age treated with combination therapy of interferon alfa-2b and ribavirin 6 % discontinued therapy due to adverse events.
V kliničnih preskušanjih pri 118 otrocih in mladostnikih, starih od 3 do 16 let, zdravljenih s kombinacijo interferona alfa-2b in ribavirina, so pri 6 % ukinili terapijo zaradi neželenih učinkov.
In clinical trials of 118 children or adolescents 3 to 16 years of age, treated with combination therapy of interferon alfa-2b and ribavirin, 6 % discontinued therapy due to adverse events.
V kliničnih preskušanjih pri 118 otrocih in mladostnikih, starih od 3 do 16 let, zdravljenih s kombinacijo interferona alfa-2b in ribavirina, so pri 6 % ukinili terapijo zaradi neželenih učinkov.
In clinical trials of 48 weeks treatment and 24 weeks follow-up, the safety profile for Pegasys in chronic hepatitis B was similar to that seen in chronic hepatitis C. With the exception of pyrexia the frequency of the majority of the reported adverse reactions was notably less in CHB patients treated with Pegasys monotherapy compared with HCV patients treated with Pegasys monotherapy (see Table
V kliničnih preskušanjih zdravljenja, ki je trajalo 48 tednov, in v obdobju sledenja bolnikov, ki je trajalo 24 tednov, je bil varnostni profil zdravila Pegasys pri bolnikih s kroničnim hepatitisom B podoben kot pri kroničnem hepatitisu C. Z izjemo pireksije je bila frekvenca večine poročanih neželenih učinkov znatno manjša pri kroničnem hepatitisu B, zdravljenem samo z zdravilom Pegasys, v primerjavi z bolniki s kroničnim hepatitisom C, zdravljenimi le z zdravilom Pegasys (glejte preglednico 9).
In clinical trials of 48 weeks treatment and 24 weeks follow-up, the safety profile for Pegasys in chronic hepatitis B was similar to that seen in chronic hepatitis C. With the exception of pyrexia the frequency of the majority of the reported adverse reactions was notably less in CHB patients treated with Pegasys monotherapy compared with HCV patients treated with Pegasys monotherapy (see Table 9).
V kliničnih preskušanjih zdravljenja, ki je trajalo 48 tednov, in v obdobju sledenja bolnikov, ki je trajalo 24 tednov, je bil varnostni profil zdravila Pegasys pri bolnikih s kroničnim hepatitisom B podoben kot pri kroničnem hepatitisu C. Z izjemo pireksije je bila frekvenca večine poročanih neželenih učinkov znatno manjša pri kroničnem hepatitisu B, zdravljenem samo z zdravilom Pegasys, v primerjavi z bolniki s kroničnim hepatitisom C, zdravljenimi le z zdravilom Pegasys (glejte preglednico 9).
In clinical trials of antiretroviral treatment naive patients treated with unboosted atazanavir, the I50L substitution, sometimes in combination with an A71V change, is the signature resistance substitution for atazanavir.
V kliničnih preskušanjih pri bolnikih, ki se predhodno še niso zdravili s protiretrovirusnimi zdravili, je bila pri zdravljenju z atazanavirjem brez okrepitve farmakokinetike substitucija I50L, včasih v kombinaciji s spremembo A71V, značilna odpornost na substitucijo proti atazanavirju.
In clinical trials of at least 2 years duration, 8% of subjects in the Eperzan group discontinued active treatment because of an adverse event compared with 6% in the all comparators group.
V kliničnih preskušanjih, ki so trajala vsaj 2 leti, je zdravilo zaradi neželenega učinka prenehalo uporabljati 8 % preiskovancev v skupini z zdravilom Eperzan in 6 % v skupini z vsemi primerjalnimi zdravili.
In clinical trials of fesoterodine, cases of markedly elevated liver enzymes were reported with the occurrence frequency no different from the placebo group.
V kliničnih preskušanjih fesoterodina je bila pogostnost izrazito zvišanih vrednosti jetrnih encimov enaka kot pri skupini, ki je prejemala placebo.
In clinical trials of HBV infected patients, the most frequently occurring adverse reaction to tenofovir disoproxil fumarate was nausea (5.4%).
V kliničnih študijah bolnikov, okuženih s HBV, je bil najpogostejši neželeni učinek, ki se je pojavljal na dizoproksiltenofovirijevega fumarata, navzea (5,4%).
In clinical trials of metastatic carcinoma of the colon or rectum, there was no increased risk of post- operative bleeding or wound healing complications observed in patients who underwent major surgery 28-60 days prior to starting Avastin.
V kliničnih preskušanjih metastatskega raka debelega črevesa in danke ni bilo povečanega tveganja za pooperativno krvavitev ali zaplete pri celjenju ran pri bolnikih, ki so imeli večjo operacijo 28 do 60 dni pred začetkom zdravljenja z zdravilom Avastin.
In clinical trials of newly diagnosed multiple myeloma in transplant non eligible patients, lenalidomide combined therapy was less tolerated in patients older than 75 years of age compared to the younger population.
V kliničnih preskušanjih novo diagnosticiranega diseminiranega plazmocitoma pri bolnikih, ki niso bili primerni za presaditev, so bolniki, starejši od 75 let, slabše prenašali kombinirano zdravljenje z lenalidomidom kot mlajša populacija.
In clinical trials of newly diagnosed multiple myeloma patients eligible for transplant, an increased incidence rate of hematologic SPM has been observed in patients receiving lenalidomide immediately following high- dose melphalan and Autologous Stem Cell Transplant (ASCT) compared with patients who received placebo (1.27 to 1.56 versus 0.46 to 0.53 per 100 person-years, respectively).
V kliničnih preskušanjih novo diagnosticiranih bolnikov z diseminiranim plazmocitomom, primernih za presaditev, so ugotovili zvečano incidenco hematoloških SPM pri bolnikih, ki so prejemali lenalidomid, ki sta mu takoj sledila melfalan v velikem odmerku in presaditev avtolognih matičnih celic (ASCT - Autologous Stem Cell Transplant), v primerjavi z bolniki, ki so prejeli placebo (1,27 do 1,56 proti 0,46 do 0,53 na 100 oseb-let).
In clinical trials of newly diagnosed multiple myeloma patients not eligible for transplant, a 4.9-fold increase in incidence rate of hematologic SPM (cases of AML, MDS) has been observed in patients receiving lenalidomide in combination with melphalan and prednisone until progression (1.75 per 100 person-years) compared with melphalan in combination with prednisone (0.36 per 100 person-years).
V kliničnih preskušanjih bolnikov z novo diagnosticiranim diseminiranim plazmocitomom, ki niso bili primerni za presaditev, so ugotovili 4,9-kratno zvečanje incidence hematoloških SPM (primeri AML, MDS) pri bolnikih, ki so prejemali lenalidomid v kombinaciji z melfalanom in prednizonom do napredovanja bolezni (1,75 na 100 oseb-let) v primerjavi z melfalanom v kombinaciji s prednizonom (0,36 na 100 oseb-let).
In clinical trials of ovarian cancer, Grade 3-5 wound healing complications were observed in up to 1.2% of patients in the bevacizumab arm versus 0.1% in the control arm (NCI-CTCAE v.3).
V kliničnih preskušanjih raka jajčnikov so zaplete pri celjenju ran stopnje 3-5 opazili pri do 1,2 % bolnic, ki so prejemale bevacizumab, v primerjavi z do 0,1 % bolnic v kontrolni skupini (NCI-CTCAE v.3).
In clinical trials of patients with Duchenne muscular dystrophy (nmDMD) caused by a nonsense mutation, the most frequent adverse reactions at the recommended dose were nausea, vomiting, and headache.
V kliničnih preskušanjih, v katerih so sodelovali bolniki z Duchennovo mišično distrofijo (DMD), ki je bila posledica nesmiselne mutacije, so bili najpogostejši neželeni učinki pri uporabi priporočenih odmerkov slabost, bruhanje in glavobol.
In clinical trials of patients with factor VII deficiency, formation of antibodies against NovoSeven and FVII is the only adverse drug reaction reported (frequency: common (≥ 1/100 to < 1/10)).
Pojav protiteles proti zdravilu NovoSeven in FVII je edini neželeni učinek zdravila, opisan v kliničnih preskušanjih bolnikov s pomanjkanjem faktorja VII, izpostavljenih zdravilu NovoSeven (pogostnost: pogosto (≥ 1/100 do < 1/10)).
In clinical trials of TESAVEL as monotherapy and as part of combination therapy with medicinal products not known to cause hypoglycaemia (i.e. metformin and/or a PPAR agonist), rates of hypoglycaemia reported with sitagliptin were similar to rates in patients taking placebo.
V kliničnih preskušanjih zdravila TESAVEL kot samostojnega zdravila in v kombinaciji z drugimi zdravili za katere ni znano, da povzročijo hipoglikemijo (tj. metforminom in/ali agonistom PPAR), so pri bolnikih, ki so jemali sitagliptin, poročali o podobnih deležih hipoglikemije kot pri bolnikih, ki so jemali placebo.
In clinical trials of treatment with oral aripiprazole, the incidence of QT prolongation was comparable to placebo.
V kliničnih preskušanjih peroralnega aripiprazola je bila pojavnost podaljšanja intervala QT primerljiva s placebom.
In clinical trials of up to 2 years duration in postmenopausal women with CE/bazedoxifene, cases of VTE have been reported (see section 4.8).
V kliničnih preskušanjih pri ženskah v postmenopavzi s CE/bazedoksifenom, ki so trajala do 2 leti, so poročali o primerih VTE (glejte poglavje 4.8).
In clinical trials of up to two years duration, pioglitazone reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels compared to placebo, metformin or gliclazide.
V kliničnih preskušanjih, ki so trajala do dve leti, je pioglitazon v primerjavi s placebom, z metforminom ali gliklazidom znižal celotno koncentracijo plazemskih trigliceridov in prostih maščobnih kislin v plazmi ter povečal koncentracijo holesterola HDL.
In clinical trials on cancer patients treated with filgrastim, the most frequent undesirable effect was musculoskeletal pain which was mild or moderate in 10% and in 3% of patients respectively.
V kliničnih preskušanjih z bolniki z rakom, zdravljenimi s filgrastimom, je bil najpogostejši neželeni učinek mišično-skeletna bolečina, ki je bila pri 10 % bolnikov blaga in pri 3 % zmerna.
In clinical trials on cancer patients treated with filgrastim, the most frequent undesirable effect was musculoskeletal pain which was mild or moderate in 10% and in 3% of patients respectively.
V kliničnih preskušanjih z bolniki z rakom, zdravljenimi s filgrastimom, je bil najpogostejši neželeni učinek mišično-skeletna bolečina, ki je bila pri 10% bolnikov blaga in pri 3% zmerna.
In clinical trials on cancer patients, the most frequent undesirable effect was musculoskeletal pain which was mild or moderate in 10%, and severe in 3% of patients.
V kliničnih preskušanjih pri bolnikih z rakom je bil najpogostejši neželeni učinek mišično-skeletna bolečina, ki je bila pri 10 % bolnikov blaga ali zmerna in pri 3 % bolnikov huda.
In clinical trials oral aripiprazole has not been shown to induce clinically relevant weight gain.
Klinična preskušanja niso pokazale, da bi peroralni aripiprazol povzročil klinično pomembno zvečanje telesne mase.
In clinical trials patients were administered aciclovir 200 mg twice a day or equivalent.
V kliničnih preskušanjih so bolniki prejemali 200 mg aciklovirja dvakrat na dan ali enakovredno zdravilo.
In clinical trials resistance to delamanid has been defined as any growth in the presence of a delamanid concentration of 0.2 μg/mL that is greater than 1% of that on drug-free control cultures on Middlebrook 7H11 medium.
V kliničnih preskušanjih so odpornost na delamanid opredelili kot vsakršno rast v prisotnosti koncentracije delamanida 0,2 μg/ml, ki je večja kot 1 % pri kontrolnih kulturah brez učinkovine v gojišču Middlebrook 7H11.
In clinical trials robenacoxib tablets reduced the lameness and inflammation of dogs with chronic osteoarthritis.
V kliničnih poskusih so tablete robenakoksiba zmanjšale šepanje in vnetje pri psih s kroničnim osteoartritisom.
In clinical trials rufinamide discontinuation was achieved by reducing the dose by approximately 25% every two days.
V kliničnih preskušanjih so dosegli ukinitev rufinamida tako, da so odmerek zmanjševali za približno 25 % vsak drugi dan.